nyx-2925
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02834741)
Timeline
Indications
Mechanism of action
GRIN3A agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C(=O)N1CCC[C@]12CN([C@H](C(N)=O)[C@@H](C)O)C2=O- Mol. weight
- 297.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095189 ↗
Also known as
- nyx-2925
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04147858 | Phase 2 | Nov 30, 2019 | Aptinyx, Syneos Health |
| NCT04146896 | Phase 2 | Oct 31, 2019 | Aptinyx, Syneos Health |
| NCT03249103 | Phase 2 | Aug 14, 2017 | Aptinyx, inVentiv |
| NCT03219320 | Phase 2 | Jun 27, 2017 | Aptinyx, Syneos Health |
| NCT02834741 | Phase 1 | Jul 1, 2016 | Aptinyx, Spaulding Clinical Research Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aptinyx | For profit | 5 | 5 | 2 | 2016 |
| Syneos Health | For profit | 3 | 0 | 1 | 2017 |
| inVentiv | For profit | 1 | 0 | 1 | 2017 |
| Spaulding Clinical Research Inc. | For profit | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1